DRG Market Assessment reports

The breast cancer therapy market in mainland China is one of the most dynamic in the oncology sector. Several new and emerging therapies are expected to gain approval for specific subpopulations,…

Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or loss of function of melanocytes. Its etiology and pathophysiology are not well understood but are believed to…

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with EGFR- and ALK-positive tumors generally receive…

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with EGFR- and ALK-positive tumors generally receive…

The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, which are prescribed for both chronic inducible urticaria (CIndU) and…

Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema. Key goals of AD treatment are to protect the skin barrier, reduce inflammation, and alleviate the itch…

China’s GLP-1 receptor agonist market is set for robust expansion, driven by the rising prevalence of type 2 diabetes (T2D), obesity, and comorbidities such as chronic kidney disease (CKD) and…

China’s biosimilar market has transformed significantly since February 2019, following the approval of Shanghai Henlius Biotech’s HLX01—a biosimilar of Roche’s MabThera (rituximab). The…

Immune checkpoint inhibitors such as Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) have transformed gastroesophageal cancer treatment, driving significant market…

The renal cell carcinoma therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens,…

Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also…

  The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 823 currently available and novel biosimilar products, detailing…